![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials
Claudio Borghi1,2, Federica Piani3, Athanasios L Manolis4
1Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy. claudio.borghi@unibo.it.
Insights
Febuxostat effectively lowers uric acid levels, offering superior efficacy for gout and hyperuricemia management, especially in patients with kidney issues. This review highlights its cardiovascular and kidney protective benefits.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Hyperuricemia increases risks for gout, chronic kidney disease (CKD), and cardiovascular disease (CVD).
- Xanthine oxidase inhibitors (XOIs) like allopurinol and Febuxostat are primary treatments for hyperuricemia with urate deposition.
- Febuxostat, a selective non-purine XOI, shows enhanced urate-lowering effects, particularly in patients with renal impairment.
Purpose of the Study:
- To review Febuxostat's pharmacological attributes.
- To analyze Febuxostat's clinical effectiveness and safety.
- To focus on Febuxostat's cardiovascular and kidney protective properties.
Main Methods:
- Literature review of pharmacological properties.
- Analysis of clinical trial data on efficacy and safety.
- Examination of studies investigating cardiovascular and renal outcomes.
Main Results:
- Febuxostat demonstrates significant urate-lowering efficacy.
- Febuxostat is particularly effective in patients with renal impairment.
- Evidence suggests potential cardiovascular and nephroprotective effects.
Conclusions:
- Febuxostat is a valuable therapeutic option for managing hyperuricemia.
- Its efficacy and safety profile, especially in renal impairment, warrant consideration.
- Further research into its cardiovascular and nephroprotective roles is supported.
Abstract:
Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat's pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
07:45Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Related Concept Videos
01:30Urinary Tract Calculi III: Medical Management
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
01:28Urinary Tract Calculi V: Nursing Management
01:25Urinary Tract Calculi VI: Surgical Management
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...